Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967478 | 1.00 | CYP1A2 (0.44) | CYP1A2ULK1NR4A2XDHDYRK1A | |
| SCHEMBL13175943 | 0.84 | DYRK1A (0.51) | CYP1A2ULK1NR4A2XDHDYRK1A | |
| SCHEMBL23102527 | 0.82 | CYP1A2 (0.44) | CYP1A2ULK1NR4A2XDHDYRK1A | |
| SCHEMBL24112892 | 0.82 | NUDT1 (0.52) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL30310440 | 0.82 | CYP1A2 (0.44) | CYP1A2ULK1NR4A2XDHDYRK1A | |
| SCHEMBL25758891 | 0.82 | ALOX15 (0.54) | DYRK1AKDM4E | |
| SCHEMBL30189256 | 0.81 | GRIN1 (0.50) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL24113095 | 0.81 | GRIN1 (0.50) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL1254304 | 0.80 | MEN1 (0.42) | CYP1A2ULK1XDHDYRK1AGABRP | |
| SCHEMBL30967524 | 0.79 | HIPK2 (0.43) | KDM4EALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2006057922-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052798-A2 | METHOD OF TREATING PATHOLOGICAL BLUSHING | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006026273-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1624871-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK CANADA INC. (CA) | 2005-12-08 | — | — | US | disclosed |
| EP-1558614-A1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | Merck Frosst Canada & Co. (CA) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004103370-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
| WO-2004039807-A1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | PTGIR, PTGIS, PTGES | CYP1A2 325/4885ULK1 2470/4885NR4A2 211/4885 |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | CYP1A2 2156/4885ULK1 3034/4885NR4A2 341/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ULK1 4791/4885NR4A2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.